OBI Pharma Announces Its In-house COVID-19 Vaccine, BCVax, can induce potent antibodies to neutralize against all variants

OBI Pharma Inc. (TPEx: 4174) announced today research results in the past six-months of their new COVID-19 Vaccine. The vaccine, named BCVax, has been proven to induce potent antibodies against COVID-19, and shown to have neutralizing activity against many SARS-CoV-2 variants. OBI has filed patent application to USPTO yesterday. Dr. Ming-Tain Lai, CSO of OBI […]

HOMEWhat’s NewNewsOBI Pharma Announces Its In-house COVID-19 Vaccine, BCVax, can induce potent antibodies to neutralize against all variants

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2022.Jan.25

OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424

2022.Feb.22

OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau